Plevitrexed (BioDeep_00000646243)

   


代谢物信息卡片


Plevitrexed

化学式: C26H25FN8O4 (532.1982701999999)
中文名称: 普来曲塞
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=CC2=C(C=C1CN(CC#C)C3=CC(=C(C=C3)C(=O)NC(CCC4=NNN=N4)C(=O)O)F)C(=O)NC(=N2)C
InChI: InChI=1S/C26H25FN8O4/c1-4-9-35(13-16-11-19-22(10-14(16)2)28-15(3)29-25(19)37)17-5-6-18(20(27)12-17)24(36)30-21(26(38)39)7-8-23-31-33-34-32-23/h1,5-6,10-12,21H,7-9,13H2,2-3H3,(H,30,36)(H,38,39)(H,28,29,37)(H,31,32,33,34)/t21-/m0/s1

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
C471 - Enzyme Inhibitor > C2021 - Thymidylate Synthase Inhibitor
D000970 - Antineoplastic Agents

同义名列表

1 个代谢物同义名

Plevitrexed



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Charlotte Rees, P Beale, Jose Manuel Trigo, Fraser Mitchell, Anne Jackman, Robert Smith, Edwin Douglass, Ian Judson. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Jun; 9(6):2049-55. doi: NULL. [PMID: 12796367]
  • Wasaburo Koizumi, Keisuke Aiba, Tsuneo Sasaki, Atsushi Sato, Noboru Horikoshi. Phase I dose-escalation trial of ZD9331 in Japanese patients with refractory, solid malignancies. Anti-cancer drugs. 2003 May; 14 Suppl 1(?):S1-5. doi: 10.1097/00001813-200305001-00001. [PMID: 14567434]
  • Ruth Plummer, Charlotte Rees, Andrew Hughes, Philip Beale, Martin Highley, Jose Trigo, Sathyarathnarn Gokul, Ian Judson, Hilary Calvert, Ann Jackman, Fraser Mitchell, Robert Smith, Edwin Douglass. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Apr; 9(4):1313-22. doi: NULL. [PMID: 12684399]
  • Maja J A de Jonge, B Glimelius, Jaap Verweij, C Van Groeningen, J Bonneterre, E G E de Vries, S Culine, J Young, Rob Smith, J Droz. Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anti-cancer drugs. 2002 Jul; 13(6):645-53. doi: 10.1097/00001813-200207000-00012. [PMID: 12172511]
  • Maja J A de Jonge, Cornelis J A Punt, Alex Sparreboom, André S T Planting, M E W J Peters, Jacqueline van De Schraaf, Ann Jackman, Rob Smith, Pieter H M de Mulder, Jaap Verweij. Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Apr; 20(7):1923-31. doi: 10.1200/jco.2002.07.057. [PMID: 11919253]
  • Hugo E R Ford, Fraser Mitchell, David Cunningham, David C Farrugia, Mark E Hill, Charlotte Rees, A Hilary Calvert, Ian R Judson, Ann L Jackman. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Jan; 8(1):103-9. doi: . [PMID: 11801545]
  • G W Aherne, A Hardcastle, E Ward, D Dobinson, T Crompton, M Valenti, L Brunton, A L Jackman. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Sep; 7(9):2923-30. doi: NULL. [PMID: 11555611]
  • B C Goh, M J Ratain, D Bertucci, R Smith, S Mani, N J Vogelzang, R L Schilsky, M Hutchison, M Smith, S Averbuch, E Douglass. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Mar; 19(5):1476-84. doi: 10.1200/jco.2001.19.5.1476. [PMID: 11230494]
  • F Mitchell, S Lynn, A L Jackman. Modified high-performance liquid chromatography assay for the measurement of 2'-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs. Journal of chromatography. B, Biomedical sciences and applications. 2000 Jul; 744(2):351-8. doi: 10.1016/s0378-4347(00)00260-7. [PMID: 10993524]
  • D R Newell. Clinical pharmacokinetics of antitumor antifolates. Seminars in oncology. 1999 Apr; 26(2 Suppl 6):74-81. doi: . [PMID: 10598559]
  • M I Walton, F Mitchell, G W Aherne, C J Medlow, F T Boyle, A L Jackman. The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice. British journal of cancer. 1998 Dec; 78(11):1457-63. doi: 10.1038/bjc.1998.707. [PMID: 9836478]
  • C H Takimoto. Antifolates in clinical development. Seminars in oncology. 1997 Oct; 24(5 Suppl 18):S18-40. doi: ". [PMID: 9420020]